Identification and expansion of the tumorigenic lung cancer stem cell population
By A. Eramo, F. Lotti, G. Sette, E. Pilozzi, M. Biffoni, A. D. Virgilio, C. Conticello, L. Ruco, C. Peschle, R. Maria. Cell Death and Differentiation, 2008
1,769 citations recorded by the source corpus.
Subfields: Immunology, Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/a355d5d84b6317891e2e58d0356462b47c1a85f6
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Molecular Biology
In Oncology
Citations in the corpus
- Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. (2010, background): “Lung cancer stem cells are believed to be the most important players in tumor development, metastasis, therapy resistance and cancer recurrence.(39,40) Additional investigation of the regulatory mechanism of these miRNAs and their target mRNAs may improve our understanding of the molecular pathogene”
- Aldehyde Dehydrogenase 1 Is a Tumor Stem Cell-Associated Marker in Lung Cancer (2009, background): “To determine whether the ALDH1-positive cells expressed distinct stem cell molecular markers, we tested CD133 antibody, a previously proven lung CSC marker (20), on”
- Evolution of the cancer stem cell model. (2014, background): “…numerous cancers including brain (Singh et al., 2004), head and neck (Prince et al., 2007), pancreas (Hermann et al., 2007; Li et al., 2007), lung (Eramo et al., 2008), prostate (Collins et al., 2005; Patrawala et al., 2006), colon (O’Brien et al., 2007; Ricci-Vitiani et al., 2007), and sarcoma…”
- Breast Cancer Stem Cells Transition between Epithelial and Mesenchymal States Reflective of their Normal Counterparts (2013, background): “Subsequently, CD44, CD24, and ALDH were reported to be expressed in CSCs from a wide variety of carcinomas, including those of the pancreas, colon, lung, ovary, and prostate gland (Eramo et al., 2008; Huang et al., 2009; Kryczek et al., 2012; Li et al., 2007; Prince et al., 2007).”
- Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. (2012, critical): “In contrast, our results on CD133 are different from the results reported by Eramo et al. (2008) even though both studies used the same CD133 antibody.”
- Mechanisms of chemoresistance in cancer stem cells (2013, background): “This includes the identification of solid tumor CSCs in a variety of organs including liver, brain, colon, pancreas, lung, ovaries and prostate [9-11,14-17].”
- Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition (2008, background): “Over the past few years, candidate cancer stem cells have been identified in a variety of human malignancies including leukemias and a number of solid tumors such as glioblastomas, medulloblastomas and carcinomas [11–24].”
- Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment (2009, background): “Long-term cultures of sphere-growing cells derived from human lung tumors were shown to be highly enriched for CD133 expression, able to self-renew, and able to be the only tumorigenic population in vivo (18).”
- Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. (2010, background): “Eramo and colleagues demonstrated that the small population of lung cancer–initiating cells could be identified by the CD133 surface marker (27).”
- Identification of Gastric Cancer Stem Cells Using the Cell Surface Marker CD44 (2009, methodology): “Based on previous published reports regarding CSCs in solid tumors [7–21], the following markers were studied: CD24, CD44, CD133, and CD166.”